<DOC>
	<DOC>NCT02094885</DOC>
	<brief_summary>To evaluate the clinical utility of Bioseal as an adjunct to control bleeding during elective vascular surgery.</brief_summary>
	<brief_title>The Bioseal Vascular Study</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>1. Subjects between 18 and 75 years of age; 2. Undergoing elective vascular surgical procedures and with the presence of an appropriate Target Bleeding Site (TBS) requiring an adjunct to achieve hemostasis as identified intraoperatively by the surgeon ; 3. Able and willing to comply with procedures required by protocol; 4. Signed and dated written informed consent prior to any study related procedures. 1. Subjects with any intraoperative findings that may preclude conducting of the study procedures; 2. Intended use of Fibrin Sealants (including autologous Fibrin Sealants) other than Bioseal on the TBS; 3. Subjects with known intolerance to blood products or to one of the components of the study product or unwilling to receive blood products; 4. Subjects with known allergies to or previously used porcine derived products; 5. Female subjects who are known breastfeeding or pregnant or intend to become pregnant during the clinical study period. 6. The subject, in the opinion of the investigator, would not be suitable for participation in the study. 7. Subjects who participated in another trial within 30 days prior to the planned start of treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>